期刊
IMMUNOLOGY AND CELL BIOLOGY
卷 99, 期 9, 页码 972-989出版社
WILEY
DOI: 10.1111/imcb.12485
关键词
helicase antigen; metastasis; treatment; triple-negative breast cancer; vaccine
资金
- John and Lucille van Geest Foundation
Managing patients with triple-negative breast cancer (TNBC) remains a clinical challenge, but the ImmunoBody-HAGE vaccine can generate specific T-cell responses and recognize TNBC cells as well as other cancer cells.
The management of patients with triple-negative breast cancer (TNBC) continues to pose a significant clinical challenge. Less than 30% of women with metastatic TNBC survive 5 years, despite adjuvant chemotherapy and the initial higher rates of clinical response that can be achieved with neoadjuvant chemotherapy. ImmunoBody is a plasmid DNA designed to encode a human antibody molecule with complementarity-determining regions engineered to express cytotoxic and helper T-cell epitopes derived from the cancer antigen of interest. The helicase antigen (HAGE) is a cancer testis antigen, which is expressed in TNBC. Herein, we have identified a 30-amino-acid-long HAGE-derived sequence containing human leukocyte antigen (HLA)-A2- and HLA-DR1-restricted epitopes and demonstrated that the use of this sequence as a peptide (with CpG/incomplete Freund's adjuvant) or incorporated into an ImmunoBody vaccine can generate specific interferon-gamma-secreting splenocytes in HHDII(+)DR1(+) mice. T-cell responses elicited by the ImmunoBody-HAGE vaccine were superior to peptide immunization. Moreover, splenocytes from ImmunoBody-HAGE-vaccinated mice stimulated in vitro could recognize HAGE(+) tumor cells and the human TNBC cell line MDA-MB-231. More importantly, the growth of implanted HHDII(+)DR1(+)HAGE(+)Luc(+) B16 cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据